{
    "clinical_study": {
        "@rank": "114328", 
        "arm_group": [
            {
                "arm_group_label": "DW1029M", 
                "arm_group_type": "Experimental", 
                "description": "DW1029M 600mg, bid, 24weeks DW1029M 1200mg, bid, 24weeks"
            }, 
            {
                "arm_group_label": "placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "placebo 600mg/1200mg, bid, 24weeks"
            }
        ], 
        "brief_summary": {
            "textblock": "A Phase \u2161, prospective, 24 weeks, double-blind, placebo-controlled, randomized, multi-center\n      clinical trial for the evaluation of the efficacy and safety of DW1029M on microalbuminuria\n      in Patients With Diabetic Nephropathy"
        }, 
        "brief_title": "To Determine the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy", 
        "completion_date": {
            "#text": "October 2014", 
            "@type": "Anticipated"
        }, 
        "condition": "Diabetic Nephropathy", 
        "condition_browse": {
            "mesh_term": [
                "Diabetic Nephropathies", 
                "Kidney Diseases"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Has confirmed diabetic mellitus prior to 6years\n\n          -  Has confirmed microalbuminuria 30 ~ 299\u338d/\u338ecreatinine prior to 5months one time and\n             microalbuminuria 30 ~ 299\u338d/\u338ecreatinine during screening period\n\n          -  BP \u2264 150 / 90 mmHg\n\n          -  eGFR \u2265 30 ml/min/1.73m2\n\n          -  HbA1c \u2264 9%\n\n          -  LDL-C \u2264 130mg/dl\n\n        Exclusion Criteria:\n\n          -  kidney or liver disease as follows i.Serum Creatinine > 2.0mg/dl ii.ALT \ub610\ub294 AST > 2 x\n             ULN iii.Total Bilirubin > 2 x ULN\n\n          -  Organic gastrointestinal disorder or Chronic gastroenterologic disorders prior to 6\n             months as follows [NOTE] Active Crohn's disease, Active ulcerative colitis, Chronic\n             peptic ulcer disease, etc.\n\n          -  cardiovascular disease prior to 3 months as follows [NOTE] Unstable angina pectoris,\n             Myocardial infarction, Coronary artery bypass surgery, Percutaneous Transluminal\n             Coronary Angioplasty, transient ischemic attack, cerebrovascular accident etc."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "30 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 30, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01935167", 
            "org_study_id": "DW1029M"
        }, 
        "intervention": [
            {
                "arm_group_label": "DW1029M", 
                "description": "DW1029M 600mg/1200mg", 
                "intervention_name": "DW1029M", 
                "intervention_type": "Drug", 
                "other_name": [
                    "DW1029M 600mg", 
                    "DW1029M 1200mg"
                ]
            }, 
            {
                "arm_group_label": "placebo", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "is_fda_regulated": "No", 
        "lastchanged_date": "September 3, 2013", 
        "location": {
            "contact": {
                "email": "keunhee.kim@dong-wha.co.kr", 
                "last_name": "Keunhee Kim, manager", 
                "phone": "82-2-2021-9554"
            }, 
            "facility": {
                "address": {
                    "city": "Seoul", 
                    "country": "Korea, Republic of", 
                    "zip": "100-130"
                }, 
                "name": "DongWha Pharm"
            }, 
            "status": "Not yet recruiting"
        }, 
        "location_countries": {
            "country": "Korea, Republic of"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Phase \u2161, Prospective, 24 Weeks, Double-blind, Placebo-controlled, Randomized, Multi-center Clinical Trial for the Evaluation of the Efficacy and Safety of DW1029M on Microalbuminuria in Patients With Diabetic Nephropathy", 
        "overall_contact": {
            "email": "keunhee.kim@dong-wha.co.kr", 
            "last_name": "Keunhee Kim, manager", 
            "phone": "82-2-2021-9554"
        }, 
        "overall_official": {
            "affiliation": "Samsung Medical Center", 
            "last_name": "MoonKyu Lee, Professor", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "Korea: Ministry of Food and Drug Safety", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "August 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "measure": "log ACR", 
            "safety_issue": "No", 
            "time_frame": "at 24 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01935167"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "Dong Wha Pharmaceutical Co. Ltd.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Dong Wha Pharmaceutical Co. Ltd.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "October 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}